A1ZN34:BVMF
AstraZeneca
139,90 BRL
0,00%
(0,00) 1D
16. okt., 17:06:00 GMT -3 · BRL
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za A1ZN34 …
Odpri
143,33 BRL
Visoka
143,33 BRL
Nizka
138,81 BRL
Tržna kapitalizacija
259,42 mrd.
Povprečni promet
892,00
Promet
1,25 tis.
52-tedenski najvišji tečaj
190,40 BRL
52-tedenski najnižji tečaj
129,06 BRL
Št. izdanih delnic
1,55 mrd.
Št. zaposlenih
96 tis.
Odpri
143,33 BRL
Visoka
143,33 BRL
Nizka
138,81 BRL
Tržna kapitalizacija
259,42 mrd.
Povprečni promet
892,00
Promet
1,25 tis.
52-tedenski najvišji tečaj
190,40 BRL
52-tedenski najnižji tečaj
129,06 BRL
Št. izdanih delnic
1,55 mrd.
Št. zaposlenih
96 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
Insider Monkey
·
pred 12 urami
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?
Traders Union
·
pred 20 urami
AstraZeneca shares technical analysis: Upward price move confirms strong near-term momentum
JournalArta
·
pred 1 dnevom
AstraZeneca Stock Analysis: Gains 3.24%, Testing Key Resistance
Reuters
·
pred 1 dnevom
AstraZeneca strikes $40 million AI drug discovery deal with insitro
Profil
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Vizitka: AstraZeneca
Generalni direktorPascal Soriot
Št. zaposlenih96,1 tis.
Ustanovljeno6. apr. 1999
SedežCambridge, Cambridgeshire, Združeno kraljestvo
Sektor-
Spletno mestoastrazeneca.com